Screening for parvovirus B19 antigen through chemiluminescent enzyme immunoassay is equivalent to B19 nucleic acid amplification test-based screening of pooled plasma.
Motonori IkegawaShinichi OhashiTakao MinagiHiroko OkamotoMikihiro YunokiPublished in: Transfusion (2021)
The results suggest that the B19-CLEIA donor screening for plasma pools is also useful in light of the US FDA recommendation.